Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Trial of Temsirolimus vs Sorafenib as Second-Line Therapy in Advanced Renal Cell Carcinoma
2007-000062-20Phase 3Completed
- Sponsor
- Wyeth
- Start
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in metastatic renal cell carcinoma (mRCC) comparing Temsirolimus arm with Sorafenib arm (2 arms). Primary endpoint: Progression-free survival by independent assessment. Started Jul 2007; status: completed.
02
Drugs
temsirolimussorafenib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on 2007-000062-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000062-20.